APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte-Colony Stimulating Factor (G-CSF)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchGranulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF) include Changchun GeneScience Pharmaceutical, Evive Biotech, Teva, CSPC Baike Biopharma, Shanghai Sunway Biotech, Sandoz, Amoytop Biotech, Qilu Pharmaceutical and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulocyte-Colony Stimulating Factor (G-CSF) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocyte-Colony Stimulating Factor (G-CSF) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulocyte-Colony Stimulating Factor (G-CSF) market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company

Changchun GeneScience Pharmaceutical

Evive Biotech

Teva

CSPC Baike Biopharma

Shanghai Sunway Biotech

Sandoz

Amoytop Biotech

Qilu Pharmaceutical

Mylan

Lunan Pharmaceutical

Kexing Biopharm

Jiangsu Hengrui Pharmaceuticals

Pfizer

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

SL Pharm

Amgen

Tanvex BioPharma

Kashiv BioSciences

Italfarmaco SpA

Coherus BioSciences

Chugai Pharmaceutical

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Long-acting G-CSF

Short-acting G-CSF

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Neutropenia

Other

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulocyte-Colony Stimulating Factor (G-CSF) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Granulocyte-Colony Stimulating Factor (G-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Granulocyte-Colony Stimulating Factor (G-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends Table 2. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers Table 3. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges Table 4. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers Table 9. Global Granulocyte-Colony Stimulating Factor (G-CSF) Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers, Product Type & Application Table 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Long-acting G-CSF Table 17. Major Manufacturers of Short-acting G-CSF Table 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (k units) Table 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (k units) Table 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026) Table 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2027-2032) Table 23. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (k units) Table 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (k units) Table 26. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026) Table 27. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Neutropenia Table 29. Major Manufacturers of Other Table 30. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (k units) Table 32. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (k units) Table 33. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026) Table 34. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2027-2032) Table 35. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (k units) Table 37. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (k units) Table 38. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2026) Table 39. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2027-2032) Table 40. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (k units) Table 42. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026) Table 43. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 47. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 48. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 50. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 57. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2026) Table 61. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2027-2032) Table 62. Changchun GeneScience Pharmaceutical Company Information Table 63. Changchun GeneScience Pharmaceutical Business Overview Table 64. Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 66. Changchun GeneScience Pharmaceutical Recent Development Table 67. Evive Biotech Company Information Table 68. Evive Biotech Business Overview Table 69. Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 71. Evive Biotech Recent Development Table 72. Teva Company Information Table 73. Teva Business Overview Table 74. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 76. Teva Recent Development Table 77. CSPC Baike Biopharma Company Information Table 78. CSPC Baike Biopharma Business Overview Table 79. CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 81. CSPC Baike Biopharma Recent Development Table 82. Shanghai Sunway Biotech Company Information Table 83. Shanghai Sunway Biotech Business Overview Table 84. Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 86. Shanghai Sunway Biotech Recent Development Table 87. Sandoz Company Information Table 88. Sandoz Business Overview Table 89. Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 91. Sandoz Recent Development Table 92. Amoytop Biotech Company Information Table 93. Amoytop Biotech Business Overview Table 94. Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 96. Amoytop Biotech Recent Development Table 97. Qilu Pharmaceutical Company Information Table 98. Qilu Pharmaceutical Business Overview Table 99. Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 101. Qilu Pharmaceutical Recent Development Table 102. Mylan Company Information Table 103. Mylan Business Overview Table 104. Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 106. Mylan Recent Development Table 107. Lunan Pharmaceutical Company Information Table 108. Lunan Pharmaceutical Business Overview Table 109. Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 111. Lunan Pharmaceutical Recent Development Table 112. Kexing Biopharm Company Information Table 113. Kexing Biopharm Business Overview Table 114. Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 116. Kexing Biopharm Recent Development Table 117. Jiangsu Hengrui Pharmaceuticals Company Information Table 118. Jiangsu Hengrui Pharmaceuticals Business Overview Table 119. Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 121. Jiangsu Hengrui Pharmaceuticals Recent Development Table 122. Pfizer Company Information Table 123. Pfizer Business Overview Table 124. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 126. Pfizer Recent Development Table 127. North China Pharmaceutical Company Information Table 128. North China Pharmaceutical Business Overview Table 129. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 131. North China Pharmaceutical Recent Development Table 132. Hangzhou Jiuyuan Gene Engineering Company Information Table 133. Hangzhou Jiuyuan Gene Engineering Business Overview Table 134. Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 136. Hangzhou Jiuyuan Gene Engineering Recent Development Table 137. Harbin Pharmaceutical Group Company Information Table 138. Harbin Pharmaceutical Group Business Overview Table 139. Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 141. Harbin Pharmaceutical Group Recent Development Table 142. SL Pharm Company Information Table 143. SL Pharm Business Overview Table 144. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 146. SL Pharm Recent Development Table 147. Amgen Company Information Table 148. Amgen Business Overview Table 149. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 151. Amgen Recent Development Table 152. Tanvex BioPharma Company Information Table 153. Tanvex BioPharma Business Overview Table 154. Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 156. Tanvex BioPharma Recent Development Table 157. Kashiv BioSciences Company Information Table 158. Kashiv BioSciences Business Overview Table 159. Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 161. Kashiv BioSciences Recent Development Table 162. Italfarmaco SpA Company Information Table 163. Italfarmaco SpA Business Overview Table 164. Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 166. Italfarmaco SpA Recent Development Table 167. Coherus BioSciences Company Information Table 168. Coherus BioSciences Business Overview Table 169. Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 170. Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 171. Coherus BioSciences Recent Development Table 172. Chugai Pharmaceutical Company Information Table 173. Chugai Pharmaceutical Business Overview Table 174. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 175. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 176. Chugai Pharmaceutical Recent Development Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List Table 180. Granulocyte-Colony Stimulating Factor (G-CSF) Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Granulocyte-Colony Stimulating Factor (G-CSF) Product Image Figure 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (2021-2032) & (US$ Million) Figure 4. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032) & (k units) Figure 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Long-acting G-CSF Image Figure 9. Short-acting G-CSF Image Figure 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032) Figure 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032) Figure 16. Neutropenia Image Figure 17. Other Image Figure 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032) Figure 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032) Figure 24. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 26. U.S. Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 31. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 38. China Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 46. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 57. North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 59. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Long-acting G-CSF
  • Short-acting G-CSF
Applications
  • Neutropenia
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • Evive Biotech
  • Teva
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Sandoz
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Mylan
  • Lunan Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • SL Pharm
  • Amgen
  • Tanvex BioPharma
  • Kashiv BioSciences
  • Italfarmaco SpA
  • Coherus BioSciences
  • Chugai Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
  1. 2.1 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
  2. 2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
  3. 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
  4. 2.4 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
3 Granulocyte-Colony Stimulating Factor (G-CSF) Market by Manufacturers
  1. 3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers, Product Type & Application
  7. 3.7 Global Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Granulocyte-Colony Stimulating Factor (G-CSF) Tier 1, Tier 2, and Tier 3
4 Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
  1. 4.1 Granulocyte-Colony Stimulating Factor (G-CSF) Type Introduction
  2. 4.1.1 Long-acting G-CSF
  3. 4.1.2 Short-acting G-CSF
  4. 4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type
  5. 4.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  7. 4.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type
  9. 4.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  11. 4.3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032)
5 Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
  1. 5.1 Granulocyte-Colony Stimulating Factor (G-CSF) Application Introduction
  2. 5.1.1 Neutropenia
  3. 5.1.2 Other
  4. 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application
  5. 5.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  7. 5.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032)
  8. 5.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application
  9. 5.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  11. 5.3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032)
6 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region
  1. 6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2032)
  3. 6.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026)
  4. 6.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region
  1. 7.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region
  2. 7.1.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026)
  4. 7.1.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032)
  5. 7.1.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  8. 7.2.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  11. 7.3.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun GeneScience Pharmaceutical
  2. 8.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 8.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 8.1.3 Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  6. 8.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 8.2 Evive Biotech
  8. 8.2.1 Evive Biotech Company Information
  9. 8.2.2 Evive Biotech Business Overview
  10. 8.2.3 Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  12. 8.2.5 Evive Biotech Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 CSPC Baike Biopharma
  20. 8.4.1 CSPC Baike Biopharma Company Information
  21. 8.4.2 CSPC Baike Biopharma Business Overview
  22. 8.4.3 CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  24. 8.4.5 CSPC Baike Biopharma Recent Developments
  25. 8.5 Shanghai Sunway Biotech
  26. 8.5.1 Shanghai Sunway Biotech Company Information
  27. 8.5.2 Shanghai Sunway Biotech Business Overview
  28. 8.5.3 Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  30. 8.5.5 Shanghai Sunway Biotech Recent Developments
  31. 8.6 Sandoz
  32. 8.6.1 Sandoz Company Information
  33. 8.6.2 Sandoz Business Overview
  34. 8.6.3 Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  36. 8.6.5 Sandoz Recent Developments
  37. 8.7 Amoytop Biotech
  38. 8.7.1 Amoytop Biotech Company Information
  39. 8.7.2 Amoytop Biotech Business Overview
  40. 8.7.3 Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  42. 8.7.5 Amoytop Biotech Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Lunan Pharmaceutical
  56. 8.10.1 Lunan Pharmaceutical Company Information
  57. 8.10.2 Lunan Pharmaceutical Business Overview
  58. 8.10.3 Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  60. 8.10.5 Lunan Pharmaceutical Recent Developments
  61. 8.11 Kexing Biopharm
  62. 8.11.1 Kexing Biopharm Company Information
  63. 8.11.2 Kexing Biopharm Business Overview
  64. 8.11.3 Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  66. 8.11.5 Kexing Biopharm Recent Developments
  67. 8.12 Jiangsu Hengrui Pharmaceuticals
  68. 8.12.1 Jiangsu Hengrui Pharmaceuticals Company Information
  69. 8.12.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  70. 8.12.3 Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  72. 8.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 North China Pharmaceutical
  80. 8.14.1 North China Pharmaceutical Company Information
  81. 8.14.2 North China Pharmaceutical Business Overview
  82. 8.14.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  84. 8.14.5 North China Pharmaceutical Recent Developments
  85. 8.15 Hangzhou Jiuyuan Gene Engineering
  86. 8.15.1 Hangzhou Jiuyuan Gene Engineering Company Information
  87. 8.15.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  88. 8.15.3 Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  90. 8.15.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  91. 8.16 Harbin Pharmaceutical Group
  92. 8.16.1 Harbin Pharmaceutical Group Company Information
  93. 8.16.2 Harbin Pharmaceutical Group Business Overview
  94. 8.16.3 Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  96. 8.16.5 Harbin Pharmaceutical Group Recent Developments
  97. 8.17 SL Pharm
  98. 8.17.1 SL Pharm Company Information
  99. 8.17.2 SL Pharm Business Overview
  100. 8.17.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  102. 8.17.5 SL Pharm Recent Developments
  103. 8.18 Amgen
  104. 8.18.1 Amgen Company Information
  105. 8.18.2 Amgen Business Overview
  106. 8.18.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  108. 8.18.5 Amgen Recent Developments
  109. 8.19 Tanvex BioPharma
  110. 8.19.1 Tanvex BioPharma Company Information
  111. 8.19.2 Tanvex BioPharma Business Overview
  112. 8.19.3 Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  114. 8.19.5 Tanvex BioPharma Recent Developments
  115. 8.20 Kashiv BioSciences
  116. 8.20.1 Kashiv BioSciences Company Information
  117. 8.20.2 Kashiv BioSciences Business Overview
  118. 8.20.3 Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  120. 8.20.5 Kashiv BioSciences Recent Developments
  121. 8.21 Italfarmaco SpA
  122. 8.21.1 Italfarmaco SpA Company Information
  123. 8.21.2 Italfarmaco SpA Business Overview
  124. 8.21.3 Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  126. 8.21.5 Italfarmaco SpA Recent Developments
  127. 8.22 Coherus BioSciences
  128. 8.22.1 Coherus BioSciences Company Information
  129. 8.22.2 Coherus BioSciences Business Overview
  130. 8.22.3 Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  132. 8.22.5 Coherus BioSciences Recent Developments
  133. 8.23 Chugai Pharmaceutical
  134. 8.23.1 Chugai Pharmaceutical Company Information
  135. 8.23.2 Chugai Pharmaceutical Business Overview
  136. 8.23.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  138. 8.23.5 Chugai Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
  2. 9.1.1 Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process
  6. 9.2 Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
  9. 9.2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst